CTMX

CytomX Therapeutics, Inc.

CTMX · CIK 1501989 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$138M
20172024
Net Income$32M
20172024
Operating CF−$86M
20172024
Free Cash Flow−$87M
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
SG&A Expense————————
Operating Income$0.0B$-0.0B$-0.1B$-0.1B$-0.0B$-0.1B$-0.0B$-0.0B
Net Income$0.0B$-0.0B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B$0.0B
EPS (Basic)————————
EPS (Diluted)————————

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.1B$0.2B$0.3B$0.3B$0.4B$0.3B$0.5B$0.4B
Current Assets$0.1B$0.2B$0.2B$0.3B$0.3B$0.3B$0.4B$0.4B
Cash & Equivalents$0.0B$0.0B$0.2B$0.2B$0.2B$0.2B$0.2B$0.2B
Total Liabilities$0.1B$0.2B$0.3B$0.3B$0.3B$0.3B$0.3B$0.3B
Current Liabilities$0.1B$0.2B$0.2B$0.1B$0.1B$0.1B$0.1B$0.1B
Stockholders' Equity$-0.0B$-0.0B$-0.1B$0.1B$0.0B$0.1B$0.1B$0.1B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.1B$0.0B$-0.1B$-0.1B—
Investing Cash Flow$0.1B$-0.2B$0.1B$0.0B$-0.0B$0.1B$0.0B—
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.0B$0.1B$0.0B$0.0B$0.1B—
← Companies